Article Text

Download PDFPDF
Prevailing practices in the treatment of tuberculous meningitis (TBM): a cross-sectional study
  1. Deepti Vibha,
  2. Kameshwar Prasad
  1. Neurology, All India Institute of Medical Sciences, New Delhi, India
  1. Correspondence to Dr Deepti Vibha, Neurology, All India Institute of Medical Sciences, New Delhi 110029, India; deeptivibha{at}yahoo.com

Statistics from Altmetric.com

Introduction

Tuberculosis (TB) of the central nervous system accounts for about 1% of all cases of TB and around 10% of extrapulmonary TB.1 There are differing recommendations for treatment of tuberculous meningitis (TBM).1–3 This is due to the limited evidence on the optimal choice and duration of antitubercular treatment (ATT). Most data on treating TBM have been extrapolated from pulmonary TB.4 Although the current practice guidelines recommend treatment for TBM for 9 months,2 the duration of treatment varies across neurologists and physicians managing the disease. The intensive phase consists of 2 months of four-drug ATT and continuation phase consists of 7 months of two-drugs ATT.

Most neurologists from high-disease-burden areas prefer to give aggressive treatment for early improvement. This notion is limited to expert opinions. It is based on the anticipation that incomplete treatment may lead to increased death, relapse and neurological sequelae. On the other hand, prolonged treatment adds to adverse effects of medications, poor compliance, economic burden and drug resistance.

A country-wide survey of the current practices in the management of TBM among treating neurologists may serve as a source for identifying areas where there is clinical equipoise and develop strategies to generate evidence. We aimed to conduct an online survey among neurologists in India to know …

View Full Text

Footnotes

  • Contributors DV: concept, drafting, collection and analysis of data, drafting of manuscript. KP: concept, analysis, review of manuscript.

  • Funding This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.